{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:49:25Z","timestamp":1788983365619,"version":"build-2803163510"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Interindividual variability in sertraline exposure is substantial and may be influenced by genetic variation in drug-metabolizing enzymes as well as by concomitant medications that modify enzyme activity. This study explored the association between genetic variability in the cytochrome P450 isoforms CYP2B6, CYP2C19, and CYP2D6 and sertraline pharmacokinetics in a real-world clinical setting, accounting for medication-related phenotype modification. We conducted an observational case-series analysis including seven hospitalized patients with available pharmacogenetic data and sixteen therapeutic drug monitoring measurements of sertraline. Pharmacokinetic parameters were descriptively compared across genotype-predicted metabolic phenotypes and after adjustment for concomitant medications with potential inhibitory or inducing effects, as informed by available interaction data. Before accounting for medication-related phenotype modification within a descriptive framework, variability in sertraline exposure appeared to follow patterns consistent with genotype-predicted phenotypes related to CYP2B6, whereas limited or inconsistent patterns were observed for CYP2C19 and CYP2D6. After incorporating co-medication effects, patterns across sertraline serum concentrations, concentration-to-dose ratios, and apparent clearance were more consistent for adjusted CYP2B6 phenotypes. Adjusted CYP2C19 phenotypes showed additional variability patterns in dose-normalized exposure and clearance, while no consistent associations were observed for CYP2D6 after adjustment. The metabolite-to-parent compound ratio showed no clear relationship with either genetic or adjusted phenotypes. These findings suggest that interpretation of pharmacogenetic information for sertraline may benefit from integrating CYP2B6 and CYP2C19 genotype data with concomitant medication use. In this exploratory case series, accounting for medication-related phenotype modification revealed variability patterns that were less evident when genetic information was considered alone. Current guidelines consider CYP2B6 and CYP2C19 actionable for sertraline; our findings suggest that integrating co-medication\u2013informed interpretation with pharmacogenetic testing and therapeutic drug monitoring may further refine individualized assessment of sertraline exposure in complex clinical settings.<\/jats:p>","DOI":"10.1371\/journal.pone.0351241","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:31:55Z","timestamp":1781112715000},"page":"e0351241","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Associations of CYP2B6, CYP2C19, and CYP2D6 isoforms and phenoconversion with sertraline pharmacokinetics"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4452-894X","authenticated-orcid":true,"given":"Bego\u00f1a","family":"Tapia-Alzuguren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2349-3631","authenticated-orcid":true,"given":"Covadonga","family":"Canga-Espina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Molero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Aldaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"2","key":"pone.0351241.ref001","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"BN Gaynes","year":"2020","journal-title":"Depress Anxiety"},{"issue":"2","key":"pone.0351241.ref002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.298","article-title":"Therapeutic drug monitoring: A patient management tool for precision medicine","volume":"99","author":"SH Jang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0351241.ref003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"C Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"pone.0351241.ref004","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/clinchem\/40.3.498","article-title":"Therapeutic monitoring of sertraline","volume":"40","author":"RN Gupta","year":"1994","journal-title":"Clin Chem"},{"issue":"5","key":"pone.0351241.ref005","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1034\/j.1600-0447.2000.101005354.x","article-title":"Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients","volume":"101","author":"J Lundmark","year":"2000","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"pone.0351241.ref006","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0278-5846(01)00314-1","article-title":"Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels","volume":"26","author":"MC Mauri","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"pone.0351241.ref007","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.502","article-title":"Long-term efficacy and therapeutic drug monitoring of sertraline in major depression","volume":"18","author":"MC Mauri","year":"2003","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"pone.0351241.ref008","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/hup.599","article-title":"Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression","volume":"19","author":"M Reis","year":"2004","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"pone.0351241.ref009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"M Reis","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"8","key":"pone.0351241.ref010","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-012-0952-2","article-title":"Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions","volume":"120","author":"S Unterecker","year":"2013","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"pone.0351241.ref011","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/cpt.2354","article-title":"How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial","volume":"110","author":"EJ Cicali","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0351241.ref012","author":"DA Flockhart","year":"2024"},{"key":"pone.0351241.ref013","doi-asserted-by":"crossref","first-page":"636650","DOI":"10.3389\/fphar.2021.636650","article-title":"Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations","volume":"12","author":"CA Bousman","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0351241.ref014","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.pharep.2017.12.001","article-title":"Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction","volume":"70","author":"\u00c1F Kiss","year":"2018","journal-title":"Pharmacol Rep"},{"issue":"2","key":"pone.0351241.ref015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2001.01328.x","article-title":"Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers","volume":"51","author":"S H\u00e4gg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0351241.ref016","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/jpet.115.225680","article-title":"CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine","volume":"354","author":"M Klieber","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"pone.0351241.ref017","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FTD.0b013e3182885d9d","article-title":"Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram","volume":"35","author":"E Ostad Haji","year":"2013","journal-title":"Ther Drug Monit"},{"key":"pone.0351241.ref018","year":"2022"},{"key":"pone.0351241.ref019","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"GS Malhi","year":"2018","journal-title":"The Lancet"},{"issue":"10128","key":"pone.0351241.ref020","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"A Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"pone.0351241.ref021","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments","volume":"61","author":"SH Kennedy","year":"2016","journal-title":"Can J Psychiatry"},{"key":"pone.0351241.ref022","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1037\/amp0000904","article-title":"Summary of the clinical practice guideline for the treatment of depression across three age cohorts","volume":"77","author":"Disorders Guideline Development Panel for the Treatment of Depressive","year":"2022","journal-title":"American Psychologist"},{"issue":"1","key":"pone.0351241.ref023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants","volume":"114","author":"CA Bousman","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"pone.0351241.ref024","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","volume":"98","author":"JK Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"pone.0351241.ref025","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/cts.13347","article-title":"Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population","volume":"15","author":"LS Br\u00e5ten","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"7","key":"pone.0351241.ref026","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"H Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"pone.0351241.ref027","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6","author":"Z Desta","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"5","key":"pone.0351241.ref028","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bcpt.12938","article-title":"Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers","volume":"122","author":"M Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"pone.0351241.ref029","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects","volume":"102","author":"Y Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"pone.0351241.ref030","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"RS Obach","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"pone.0351241.ref031","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cpt.1643","article-title":"PharmVar GeneFocus: CYP2D6","author":"C Nofziger","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"pone.0351241.ref032","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11096-016-0259-8","article-title":"Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients","volume":"38","author":"N Yuce-Artun","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"pone.0351241.ref033","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-008-0533-3","article-title":"Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients","volume":"64","author":"I Rudberg","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0351241.ref034","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/a-2248-6924","article-title":"The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics","volume":"57","author":"M Scherf-Clavel","year":"2024","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"pone.0351241.ref035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41386-019-0554-x","article-title":"Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients","volume":"45","author":"LS Br\u00e5ten","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"pone.0351241.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325335","article-title":"The PREDEP-SERT study protocol: A 6-month follow-up cohort study of predictors of effectiveness, tolerability and safety of sertraline for depression using Therapeutic Drug Monitoring","volume":"20","author":"P Molero","year":"2025","journal-title":"PLoS One"},{"issue":"3","key":"pone.0351241.ref037","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database","volume":"103","author":"A Gaedigk","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0351241.ref038","author":"U.S. Food and Drug Administration","year":"2026"},{"issue":"1","key":"pone.0351241.ref039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-018-1922-0","article-title":"An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes","volume":"126","author":"S Mostafa","year":"2019","journal-title":"J Neural Transm (Vienna)"},{"key":"pone.0351241.ref040","doi-asserted-by":"crossref","first-page":"724170","DOI":"10.3389\/fpsyt.2021.724170","article-title":"Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting","volume":"12","author":"S Mostafa","year":"2021","journal-title":"Front Psychiatry"},{"issue":"5","key":"pone.0351241.ref041","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s11096-023-01588-8","article-title":"Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study","volume":"45","author":"M Scherf-Clavel","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"pone.0351241.ref042","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.1365-2125.2003.01857.x","article-title":"Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects","volume":"56","author":"K Sathirakul","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0351241.ref043","first-page":"177","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"JT Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"pone.0351241.ref044","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"MC Mauri","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"pone.0351241.ref045","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40262-015-0275-1","article-title":"The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD","volume":"54","author":"SJC Davies","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"pone.0351241.ref046","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hup.2532","article-title":"SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study","volume":"31","author":"SJC Davies","year":"2016","journal-title":"Hum Psychopharmacol"},{"key":"pone.0351241.ref047","doi-asserted-by":"crossref","first-page":"666296","DOI":"10.3389\/fphar.2021.666296","article-title":"Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole","volume":"12","author":"S-J Jia","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0351241.ref048","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1065","article-title":"Lower sertraline plasma concentration in patients co-medicated with clozapine-Implications for pharmacological augmentation strategies in schizophrenia","volume":"11","author":"AJ Gaebler","year":"2023","journal-title":"Pharmacol Res Perspect"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:32:01Z","timestamp":1781112721000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351241"}},"subtitle":[],"editor":[{"given":"Hans-Joachim","family":"Lehmler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351241","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}